CompanyGraph
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
3613 · HKEX · Hong Kong
Price data from its TQR listing on FSX, quoted in EUR
cm.tongrentang.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $87.52M, above the global median of $16.24M
- FinancialsHigh structural barrier to entry
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
6.23%Above 5Y avg (3.25%)
Annual Rate
HKD 0.40Paid annual
Payout Ratio
74.5%Moderate
Payback Period
1.7 yr
Last Ex-Dividend
Jun 12, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.44BHKD949.13M · vs all stocks (USD)
Trailing P/E
13.80xRevenue (TTM)
1.51BHKD193.01M · vs all stocks (USD)
Profit Margin
26.25%Beta
0.3550xvs all stocks
52-Week Change
-30.89%vs all stocks
Market Capitalization
7.44BHKD949.13M · vs all stocks (USD)
Enterprise Value
3.45BHKD439.47M · vs all stocks (USD)
Trailing P/E
13.80xForward P/E
10.99xPEG Ratio
-0.1380xPrice to Sales (TTM)
3.59xPrice to Book (MRQ)
1.30xEnterprise to Revenue
2.28xEnterprise to EBITDA
6.95xProfit Margin
26.25%Operating Margin
28.03%Return on Assets (TTM)
6.45%Return on Equity (TTM)
9.68%Revenue (TTM)
1.51BHKD193.01M · vs all stocks (USD)
Revenue per Share (TTM)
1.81HKDUpdated Aug 20, 2026Quarterly Revenue Growth
-20.60%Gross Profit (TTM)
925.58MHKD118.05M · vs all stocks (USD)
EBITDA (TTM)
674.26MHKD86.00M · vs all stocks (USD)
Net Income (TTM)
397.22MHKD50.66M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-42.10%Operating Cash Flow (TTM)
829.52MHKD105.80M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
686.19MHKD87.52M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.4000HKDUpdated Aug 20, 2026Trailing Annual Dividend Yield
6.23%vs all stocks
5-Year Average Dividend Yield
3.25%vs all stocks
Payout Ratio
74.47%Minority Interest (Equity)
180.97MHKDFY2025 · Dec 31, 2025EPS (Basic)
0.4700HKDFY2025 · Dec 31, 2025EPS (Diluted)
0.4700HKDFY2025 · Dec 31, 2025Basic Shares Outstanding
837.10MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
837.10MSharesFY2025 · Dec 31, 2025Operating Cash Flow
772.22MHKDFY2025 · Dec 31, 2025Free Cash Flow
731.11MHKDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.23BHKDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
504.69MHKDFY2025 · Dec 31, 2025Other Non-cash Items
-41.17MHKDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
58.98MHKDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
249.72MHKDFY2025 · Dec 31, 2025Capital Expenditures
-41.10MHKDFY2025 · Dec 31, 2025Net Investing Cash Flow
-41.10MHKDFY2025 · Dec 31, 2025Long-term Debt Payments
-71.00KHKDFY2025 · Dec 31, 2025Common Dividends Paid
-292.99MHKDFY2025 · Dec 31, 2025Other Financing Charges
8.07MHKDFY2025 · Dec 31, 2025Net Financing Cash Flow
-284.99MHKDFY2025 · Dec 31, 2025Shares Outstanding
837.10MSharesUpdated Aug 20, 2026Float Shares
237.10MSharesUpdated Aug 20, 2026% Held by Insiders
71.68%vs all stocks
% Held by Institutions
3.06%vs all stocks
Total Cash (MRQ)
2.29BHKD292.11M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.74HKDUpdated Aug 20, 2026Total Debt (MRQ)
126.54MHKD16.14M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0290xCurrent Ratio (MRQ)
19.65xBook Value per Share (MRQ)
5.00HKDUpdated Aug 20, 2026Total Assets
4.66BHKD594.43M · vs all stocks (USD)
Total Current Assets
4.06BHKDFY2025 · Dec 31, 2025Total Liabilities
291.88MHKDFY2025 · Dec 31, 2025Total Non-current Assets
595.98MHKDFY2025 · Dec 31, 2025Total Non-current Liabilities
85.03MHKDFY2025 · Dec 31, 2025Total Current Liabilities
206.85MHKDFY2025 · Dec 31, 2025Cash
438.05MHKDFY2025 · Dec 31, 2025Cash Equivalents
1.79BHKDFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.23BHKDFY2025 · Dec 31, 2025Other Short-term Investments
51.38MHKDFY2025 · Dec 31, 2025Accounts Receivable
394.87MHKDFY2025 · Dec 31, 2025Inventory
1.34BHKDFY2025 · Dec 31, 2025Accounts Payable
62.03MHKDFY2025 · Dec 31, 2025Short-term Debt
52.30MHKDFY2025 · Dec 31, 2025Long-term Debt
74.24MHKDFY2025 · Dec 31, 2025Common Stock (Book)
938.79MHKDFY2025 · Dec 31, 2025Retained Earnings
3.30BHKDFY2025 · Dec 31, 2025Total Shareholders' Equity
4.37BHKD557.20M · vs all stocks (USD)
52-Week Low
6.21HKDUpdated Aug 20, 202652-Week High
9.72HKDUpdated Aug 20, 202652-Week Change
-30.89%vs all stocks
Beta
0.3550xvs all stocks
50-Day MA
6.69HKDUpdated Aug 20, 2026200-Day MA
7.90HKDUpdated Aug 20, 2026Avg 10-Day Volume
695.30KSharesUpdated Aug 20, 2026Avg 30-Day Volume
771.72KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.4700HKDUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.56
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $87.52M, above the global median of $16.24MNotable
Levered free cash flow (USD): 87,516,576.69Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Annexon, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Bailing Group Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hob Biotech Group Suzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arbutus Biopharma Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Seegene, Inc.
Tier 1ProductionApproval-Gated PipelineRule